This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AZD1152
Description: AZD1152 is being evaluated to determine its effect as a specific inhibitor of Aurora kinase and its impact on cell division in proliferating tumors. It has been shown to inhibit spindle aggregation at the time of mitosis.
AstraZeneca and BIND
In April 2013, AstraZeneca and BIND announced that they have entered into a strategic collaboration to develop and commercialise an Accurin based on AstraZeneca's prodrug Barasertib (AZD1152) with optimal critical nanoparticle properties such that a short infusion has the potential for extended target cover from increased biodistribution to the tumor site.
Under the terms of the agreement, the companies will work together to complete Investigational New Drug (IND)-enabling studies of the lead Accurin identified from a previously-completed feasibility program. AstraZeneca will then have the exclusive right to lead development and commercialization and BIND will lead manufacturing during the development phase. BIND could receive upfront and pre-approval milestone payments totaling $69 million, and more than $130 million in regulatory and sales milestones and other payments as well as tiered single to double-digit royalties on future...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Additional information available to subscribers only: